India to achieve 100% vaccination goal against the deadly Virus
A health worker prepares a dose of the COVID-19 vaccine Covishield for health workers of the Border Security Force at Agartala,
More than 2.3 million people in India reportedly have received vaccinations against the Wuhan Virus as of Wednesday, the twelfth day since the country launched its “world’s biggest inoculation program” that plans to vaccinate 300 million population from high-risk groups in the first phase. The program is moving ahead as per plan and gathering speed day by day.
Though earlier many international observers had, like all other things with respect to India,doubted it. They believed that due to such a huge ambitious target it will lead to failure. As usual they have been surprised, especially China whose Communist Party had even been questioning the ability of India to produce a Vaccine. Next they had started questioning its efficacy.
India will achieve “100 percent ” goal of vaccination as per plan. Though people like Tian Guangqiang, assistant research fellow with the National Institute of International Strategy at the Chinese Academy of Social Sciences, are spreading rumours that Indians are distrusting the vaccine and there is even heavy short supply.
It seems, the Chinese have not liked the gifting of millions of doses of the vaccine by India to its friendly neighbours and other friendly countries. Such goodwill gestures are causing huge bellyaches to the Chinese.
Chinese authorities are trying to highlight incidents of the deaths of nine health workers following vaccination in the first 12 days since the inoculation started on January 16. Though these deaths have been due to other causes and the Indian authorities have clarified that the deaths were not due to the vaccine. The vaccine taken in each case was Oxford/AstraZeneca’s Covishield.
The newly developed adenovirus vector vaccine, Covishield’s stability and security is relatively quite high than the more mature inactivated vaccines, and it has shown very mild adverse reactions in its clinical trials.
Though Global Times likes to keep repeating “It’s better for India to suspend Covishield inoculations before finding out the actual causes of the nine deaths.”
It tries to cite a German immunization commission report that has recommended the government only use it on people between the ages of 18 and 64, as “there was insufficient information on its effectiveness for people over 65 years old,” according to Bloomberg.
India’s self-developed COVID-19 vaccine Covaxin, also available in the country’s current domestic inoculations apart from Covishield, is also becoming popular day by day.
United Nations Secretary-General Antonio Guterres on Thursday praised India’s “high level of production” of vaccines, reported Delhi-based newspaper Mint on Friday. The country’s largest producer Serum Institute of India (SII) told the BBC earlier this month that it could make 50 million doses a month. The capacity has already been increased and will soon be doubled.
The Indian achievement has given a tight slap even to ECONOMIST which recently listed both India and China as third echelon countries in the world to achieve “widespread” vaccination coverage – meaning 60-70 percent of the adult population being vaccinated.
ECONOMIST as usual thinks that the two populous countries will have widespread access to the shots only in late 2022, later than many developed Western countries and middle-income ones including Mexico and Brazil. Some people never learn till they receive a kuck on their rear.
